ArQule, Inc. (ARQL)
(Delayed Data from NSDQ)
$6.51 USD
+0.23 (3.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.51 USD
+0.23 (3.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Biotech ETFs Hit New Highs on Deal Activities
by Sweta Killa
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Company News for Dec 10, 2019
by Zacks Equity Research
Companies in the news are: ARQL, THOR, CGC, FATE
Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms
by Kinjel Shah
Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.
Week Begins with Biotech Mergers
by Zacks Equity Research
Week Begins with Biotech Mergers
Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More
by Mark Vickery
Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).
ArQule (ARQL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ArQule (ARQL) delivered earnings and revenue surprises of 0.00% and -82.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About ArQule (ARQL) Rating Upgrade to Buy
by Zacks Equity Research
ArQule (ARQL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ArQule (ARQL) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
ArQule (ARQL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
ArQule (ARQL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ArQule (ARQL) delivered earnings and revenue surprises of 11.11% and -80.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
Analysts Estimate ArQule (ARQL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ArQule (ARQL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes ArQule (ARQL) a New Buy Stock
by Zacks Equity Research
ArQule (ARQL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Do Options Traders Know Something About ArQule (ARQL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.
ArQule (ARQL) Catches Eye: Stock Jumps 8.1%
by Zacks Equity Research
ArQule (ARQL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Company News For Jun 17, 2019
by Zacks Equity Research
Companies In The News Are: FB,BXG,ARQL,KURA
ArQule (ARQL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ArQule (ARQL) delivered earnings and revenue surprises of -12.50% and -20.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ArQule (ARQL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ArQule (ARQL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About ArQule (ARQL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in ArQule (ARQL) Stock
by Zacks Equity Research
ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in ArQule (ARQL) Stock
by Zacks Equity Research
ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.
ArQule (ARQL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ArQule (ARQL) delivered earnings and revenue surprises of 16.67% and 104.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for ArQule (ARQL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
by Zacks Equity Research
Small drugmakers, in general, are having a rather poor year, the principle reason being failure of key pipeline candidates in pivotal studies.
ArQule (ARQL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ArQule (ARQL) delivered earnings and revenue surprises of 150.00% and 78.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?